Search Patents
  • CAANABIGEROL PROLINE COCRYSTALS
    Publication number: 20220332682
    Abstract: Cannabigerol proline cocrystals are disclosed, specifically a 1:2 cannabigerol L-proline cocrystal, a 1:2 cannabigerol D-proline cocrystal and a 1:2 cannabigerol D, L-proline cocrystal and their preparation. Also disclosed are pharmaceutical compositions containing a cannabigerol proline cocrystal and a pharmaceutically acceptable excipient as well as methods and uses of a cannabigerol proline cocrystal or pharmaceutical composition to treat a disease, disorder or condition by administering to a patient in need thereof a therapeutically effective amount of a cannabigerol proline cocrystal or a pharmaceutical composition containing a cannabigerol proline cocrystal. Also disclosed are processes for the preparation of crystalline cannabigerol, Forms I, II and III.
    Type: Application
    Filed: September 4, 2020
    Publication date: October 20, 2022
    Inventors: Joanne HOLLAND, Alex EBERLIN
  • COMPOSITIONS AND METHODS USING CANNABINOID COMPOUNDS FOR REGULATING GASTRIC ACID SECRETION TO TREAT GASTROESOPHAGEAL REFLUX DISEASE AND RELATED CONDITIONS
    Publication number: 20230047027
    Abstract: Compositions for regulating gastric acid buildup using cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabicyclol (“CBL”), cannabichromene (“CBC”), cannabidivarin (“CBDV”), cannabidol (“CBD”), cannabigerol hexyl (“CBG-C6”), cannabigerol heptyl (“CBG-C7”), cannabigerol nonyl (“CBG-C9”), cannabidol-C2 (“CBD-C2”), cannabidol hexyl (“CBD-C6”), and cannabidol heptyl (“CBD-C7”). The cannabinoid compounds can be H2 antagonists. Methods and articles including the cannabinoid compounds are further disclosed.
    Type: Application
    Filed: July 13, 2022
    Publication date: February 16, 2023
    Inventors: Cynthia W. Byrant, Alison Watta
  • METHOD TO TREAT ATOPIC DERMATITIS
    Publication number: 20190060251
    Abstract: A method to treat the skin condition atopic dermatitis is described in this invention. The method comprises topical application of a composition containing cannabinoids, specifically cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The method may further comprise administering chewing gum containing cannabinoids such as cannabidiol. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • Method to treat atopic dermatitis
    Patent number: 10272051
    Abstract: A method to treat the skin condition atopic dermatitis is described in this invention. The method comprises topical application of a composition containing cannabinoids, specifically cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The method may further comprise administering chewing gum containing cannabinoids such as cannabidiol. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: April 30, 2019
    Assignee: Axim Biotechnologies, Inc.
    Inventors: Lekhram Changoer, George Anastassov
  • METHOD TO TREAT VITILIGO
    Publication number: 20230050166
    Abstract: A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Application
    Filed: September 29, 2022
    Publication date: February 16, 2023
    Applicant: APIRx Pharmaceutical USA, LLC
    Inventors: Lekhram Changoer, George Anastassov
  • METHOD TO TREAT VITILIGO
    Publication number: 20190060252
    Abstract: A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • PHARMACEUTICAL COMPOSITION COMPRISING TETRAHYDROCANNABIVARIN FOR THE PREVENTION AND TREATMENT OF OVERWEIGHT
    Publication number: 20220168265
    Abstract: The present invention relates to a pharmaceutical composition comprising a tetrahydrocannabivarin (THCV), wherein the composition further comprises cannabigerol (CBG) or cannabinodiol (CBND) or a mixture thereof, for use in the prevention and treatment of overweight, preferably associated with obesitas. The pharmaceutical composition according to the invention may further comprise the following additional compounds tetrahydrocannabinol (THC), or Cannabigerol (CBG) or Cannabinodiol (CBND) or a combination thereof.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 2, 2022
    Inventor: Ronald Johannes GLAS
  • Extraction and Purification of Cannabinoids
    Publication number: 20230355697
    Abstract: An improved method for making cannabigerol (CBG) utilizing the following steps. CBG-containing material is contacted with an aqueous alkaline solution containing a hydroxide base and essentially no organic solvents, thereby extracting cannabinoids including carboxylic acids and salts and producing an alkaline extract. Non-soluble CBG-containing material is removed from the alkaline extract to produce a clarified alkaline extract. The extracted cannabinoids are decarboxylated and the resulting cannabigerol is crystallized/precipitated from the clarified alkaline extract at a pH greater than 7.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 9, 2023
    Inventor: Zachary White
  • Method to treat vitiligo
    Patent number: 11484510
    Abstract: A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 1, 2022
    Assignee: APIRx Pharmaceutical USA, LLC
    Inventors: Lekhram Changoer, George Anastassov
  • THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA
    Publication number: 20160136128
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 19, 2016
    Inventors: Farideh Javid, Marnie Duncan, Colin Stott
  • REGULATION OF THE SLEEP/WAKE CYCLE USING CANNABINOID COMPOUNDS
    Publication number: 20220401407
    Abstract: Methods of regulating or treating the sleep/wake cycle and related sleep disorders with cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabichromene (“CBC”), cannabicyclol (“CBL”), cannabinol (“CBN”), tetrahydrocannabivarin (“THCV”), cannabidol (“CBD”), (+)-cannabidiol (“(+)-CBD”), cannabigerol (“CBG”), and cannabigerol butyl (“CBG-C4”) and can be antagonists to the receptors HCRTR1 and HCTR2. Compositions and articles including the cannabinoid compounds are further disclosed.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 22, 2022
    Inventors: Cynthia W. Bryant, Alison Watta
  • Use of phytocannabinoids in the treatment of ovarian carcinoma
    Patent number: 10098867
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: October 16, 2018
    Assignee: GW Research Limited
    Inventors: Farideh Afshin Javid, Marnie Duncan, Colin Stott
  • FULL SPECTRUM HEMP OIL COMPOSITIONS
    Publication number: 20230097799
    Abstract: A composition comprising a cannabidiol at least one compound selected from the group consisting of cannabichromenes, cannabicyclols, cannabidiols, cannabielsoins, cannabigerols, cannabinols, cannabinodiols, cannabitriols, delta-8-tetrahydrocannabinols, delta-9-tetrahydrocannabinols, or any combination thereof; and a terpene. A nanoemulsion comprising a cannabidiol; a terpene; and an aqueous fluid, wherein the cannabidiol and terpene are in an emulsion in the aqueous fluid. A full spectrum hemp oil composition comprising at least one stereoisomer of tetrahydrocannabinol; cannabinodiol; and at least one cannabinoid selected from the group consisting of cannabichromenes, cannabicyclols, cannabidiols, cannabielsoins, cannabigerols, cannabinols, cannabinodiols, cannabitriols, and a combination thereof.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 30, 2023
    Inventors: Andrew HORVATH, Ryan RAYNAUD
  • ORAL CANNABINOID FORMULATIONS
    Publication number: 20190365667
    Abstract: The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: February 15, 2018
    Publication date: December 5, 2019
    Inventors: Stephen WRIGHT, Jitinder WILKHU
  • Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms
    Publication number: 20200367548
    Abstract: The present invention is a cannabidiol (CBD), cannabigerol (CBG) or related cannabinoid oral dosage form including bacterially fermented hemp, typically compounded as a tablet or formulated within a capsule or as an additive to other dietary supplements or functional foods. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber, which is an optimal fiber ratio for oral delivery and bioavailability of cannabidiol, cannabigerol and other desirable cannabinoids from either activated or native hemp.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 26, 2020
    Applicant: BYO Holdings, LLC
    Inventor: Jordan Seth Rubin
  • ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20170143642
    Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).
    Type: Application
    Filed: June 26, 2015
    Publication date: May 25, 2017
    Applicant: GW Pharma Limited
    Inventors: Colin Stott, Marnie Duncan, Thomas Hill
  • PARENTERAL FORMULATIONS
    Publication number: 20220096397
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Stephen WRIGHT, Jitinder Wilkhu
  • Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
    Patent number: 9962341
    Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 8, 2018
    Assignee: GW Pharma Limited
    Inventors: Colin Stott, Marnie Duncan, Thomas Hill
  • ORAL CARE PRODUCT WITH CANNABINOID COMPOUNDS
    Publication number: 20220304911
    Abstract: The present disclosure relates to compositions and methods for reducing, preventing, and/or treating oral conditions comprising the administration of one or more cannabinoid compounds to reduce Streptococcus mutans. The one or more cannabinoid compounds can include cannabigerol (“CBG”), cannabigerolic acid (“CBGA”), cannabichromene (“CBC”), cannabidivarinic acid (“CBDVA”), cannabidivarin (“CBDV”), cannabidiolic acid (“CBDA”), cannabidiol (“CBD”), cannabidiol ethyl (“CBD-C2”), cannabidibutol (“CBD-C4”), (+)-cannabidiol (“(+)-CBD”), cannabigerovarin (“CBGV”), cannabigerol butyl (“CBG-C4”), or cannabigerolic acid butyl (“CBGA-C4”). Methods of making and using the cannabinoid compounds are further disclosed.
    Type: Application
    Filed: March 26, 2022
    Publication date: September 29, 2022
    Inventors: Cynthia W. Bryant, Alison Watta
  • Oral cannabinoid formulations
    Patent number: 11426362
    Abstract: The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: August 30, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
Narrow Results

Filter by US Classification